Search

Displaying results 3031 - 3040 of 4344 in total
  1. Drug

    Digoxigenin

    go.drugbank.com/drugs/DB03671
    Experimental

    Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.

  2. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  3. Drug

    IP501

    go.drugbank.com/drugs/DB06450
    Experimental

    The compound was developed by Indevus Pharmaceuticals.

  4. Drug

    BMS-986251

    go.drugbank.com/drugs/DB19007
    Investigational

    BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

  5. Drug

    Nezastomig

    go.drugbank.com/drugs/DB19061
    Investigational

    Nezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

  6. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COV...

  7. Drug

    Calcium acetate

    go.drugbank.com/drugs/DB00258
    Approved

    The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.

  8. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  9. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  10. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.